Coronary disease & ACSSecondary analysis
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction
- Secondary analysis of the AEGIS-II randomised trial
- prespecified exploratory analysis
Authors' conclusion
In this prespecified exploratory analysis of the AEGIS-II trial, 4 weekly infusions of CSL112 among high-risk patients after AMI significantly reduced the total burden of nonfatal ischemic events and CV death at 180 and 365 days compared with placebo.
Study context
- Population
- Patients with acute myocardial infarction (AMI), multivessel CAD and additional cardiovascular (CV) risk factors
- Participants
- 18,219 patients
- Comparison
- CSL112 vs placebo
- CSL112n = 9,112
- Placebon = 9,107reference
- Primary endpoint
- Total burden of nonfatal ischemic events (recurrent MI and stroke) and CV death
Primary result
As reported in the abstract
Total CV death, MI and stroke events
90 days: 503 vs 545 events, RR 0.88 (95% CI 0.76-1.03)
P = 0.11
180 days: 745 vs 821 events, RR 0.87 (95% CI 0.77-0.99)
P = 0.04
365 days: 1,120 vs 1,211 events, RR 0.89 (95% CI 0.80-0.99)
P = 0.04
Further findings
Subsequent events as share of all events
- 90 days
- 13%
- 180 days
- 17%
- 1 year
- 22%
Total nonfatal myocardial infarction (MI) (excluding type 2) and CV death
- 90 days: RR 0.81 (95% CI 0.68-0.97)
- P = 0.02
- 180 days: RR 0.82 (95% CI 0.71-0.95)
- P < 0.01
- 365 days: RR 0.86 (95% CI 0.76-0.98)
- P = 0.02
- nominally significant
Total nonfatal MI and CV death
- Similar findings to CV death, MI and stroke
Original publication
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction. J Am Coll Cardiol. Published 2 September 2024. doi:10.1016/j.jacc.2024.08.001
Summarised from the published abstract; every number is checked against it